NewsRoom Articles - Page 165 of 228

MondayJul 19, 2021 1:30 pm

Study Finds Regular Physical Activity Boosts Brain Health in Growing Children

A recent study conducted by researchers from Boston Children’s Hospital has found that exercise assists in the organization of developing brains in growing children. The study discovered that physical activity was linked to more flexible, strong and efficiently organized brain networks. Dr. Caterina Stamoulis, who is the study’s lead, conducted an analysis of brain imaging data collected from an estimated 6,000 children between the ages of nine and ten. Stamoulis, who is also the head of the Boston Children’s Computational Neuroscience Laboratory, explained that the physical activity children engaged in didn’t matter as long as they were active. She conducted…

MondayJul 19, 2021 11:22 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

XPhyto partners with AGORA t to grow its brand and overall market share The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 AGORA is known for its online marketing, conferences, broadcasting and investor relations services Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp…

MondayJul 19, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb). "These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s…

FridayJul 16, 2021 2:05 pm

Sleep Apnea, Genetic Predisposition Linked to Severe Coronavirus Infection

A recent study conducted by researchers from the Academy of Finland has found that almost half of all coronavirus patients who also suffer from obstructive sleep apnea need to be hospitalized. The study, which was reported in the BMJ journals, noted that moderate to acute sleep apnea predisposes individuals to acute coronavirus. Other coronavirus risk factors include older age, diabetes and a high body mass index. The researchers used FinnGen data for their study, which was backed by the Center of Excellence in Complex Disease Genetics. The researchers linked data obtained from the Finland National Infectious Disease Register on coronavirus…

FridayJul 16, 2021 1:58 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate

San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists,…

FridayJul 16, 2021 9:30 am

New Research Finds Neurological Damage in Patients Hospitalized with COVID-19; Brain Scientific (BRSF) Appears Poised to Offer Technology That Can Help Understand How COVID-19 Affects Brain

Scientific evidence is mounting that SARS-CoV-2 can cause neurological damage in patients hospitalized with the infection. A recent study that appeared in the journal JAMA Network Open finds five times increased mortality risk in patients hospitalized with COVID-19, citing encephalopathy as the most common neurological disease found in the clinical setting. As more research is needed to understand how COVID-19 affects the brain, Brain Scientific appears poised to offer technology solutions as a leading player in the neurological diagnostics space. As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered…

ThursdayJul 15, 2021 1:08 pm

Report Finds That Use of Remote Health Has Grown Significantly

A recent survey conducted in the second quarter of this year by Parks Associates has found that more than one-half of broadband households own an internet-enabled fitness or health device that records biometric data, with another two-thirds revealing that they have undergone remote health consultation. The survey, which involved 5,000 broadband households in the United States was conducted by Parks Associates, a market research and consulting firm that specializes in emerging consumer technology products. Parks Associates senior analyst Kristen Hanich stated that the overall familiarity with telehealth had assisted in driving the connected health device market. Hanich noted that there…

WednesdayJul 14, 2021 11:43 am

Brain Scientific Inc. (BRSF) Announces Merger Agreement With Piezo Motion to Expand Market Reach Into Fast-Growing Multi-Billion-Dollar Markets

BRSF is about to enter into a merger agreement to acquire Piezo Motion, a leading piezo motor technology developer Piezo Motion's technology will be deployed to leverage massive amounts of data that can be analyzed by artificial intelligence to assist medical professionals and researchers in recommending adequate precision treatments Merger expected to expand markets for both companies and their potential to deliver innovative technologies to high-growth segments Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has announced that it has entered into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric…

WednesdayJul 14, 2021 10:00 am

Researchers May Have Found Way to Retain Bladder After Bladder Cancer Diagnosis

Cancer metastasis is every patient and doctor’s nightmare when it comes to treating this deadly disease. Chemotherapy is usually the primary treatment option, with doctors following up with surgeries to remove any tumors. However, patients suffering from muscle-invasive bladder cancer have to make a life-altering decision to either undergo chemotherapy and have their bladder removed to reduce chances of the cancer recurring or take their chances with the cancer metastasizing and leave their bladder intact while undergoing chemotherapy. Cystectomy, which refers to the surgical removal of the bladder, is the standard treatment plan for individuals who suffer from muscle-invasive bladder…

TuesdayJul 13, 2021 10:13 am

Study Explores Debilitating Childhood Brain Cancer Treatment Options

A recent study by the St. Jude Children’s Research Hospital and the School of Medicine at the Washington University in St. Louis proposes that young patients with an average risk medulloblastoma can, after a six-week radiation treatment regimen, undergo a radiation boost to a smaller area of the brain. Medulloblastoma is a pediatric brain cancer that usually affects the spine and/or brain and can spread through a patient’s spinal fluid. The standard of care for this type of cancer includes radiation therapy to the whole spine and brain, after which an extra dose of radiation to the back of the…